Tags

Type your tag names separated by a space and hit enter

Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma.

Abstract

BACKGROUND

Survivors of Hodgkin lymphoma (HL) are at an increased risk of developing second malignancies. To the authors' knowledge, the risks of head and neck cancer (HNC) after HL and subsequent survival have not been thoroughly investigated.

METHODS

From the US population-based Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2011, survivors of HL who developed HNC as a second cancer were analyzed. Patients with a first primary HNC were used as a comparison group. Observed-to-expected ratios and summary statistics were performed on patients with HL with squamous cell carcinoma (HL-SCC) and salivary gland cancer (HL-SGC). The impact of HL history on overall survival was assessed using a multivariate Cox proportional hazards model.

RESULTS

The observed-to-expected ratio for SCC among patients with HL was 1.73 (95% confidence interval [95% CI], 1.36-2.16; P<.05), whereas it was 8.56 for SGC (95% CI, 5.82-12.15; P<.05). Using Cox proportional hazards modeling, a history of HL was found to be an adverse prognostic factor for overall survival for SCC (hazard ratio, 1.37; 95% CI, 1.08-1.73 [P = .009]) but not SGC (hazard ratio, 1.21; 95% CI, 0.82-1.79 [P = .34]). The inferior survival of the patients in the HL-SCC cohort appears to be attributable to more deaths from HL and other malignancies diagnosed after SCC.

CONCLUSIONS

There is a significantly increased risk of salivary and nonsalivary HNC after HL, and worse survival for patients with HL-SCC versus those with a first primary SCC. Clinicians should be aware of the risks of HNC after HL. In the absence of evidence-based criteria, the authors recommend that survivors of HL undergo periodic head and neck examination.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York.

    , , , ,

    Source

    Cancer 121:9 2015 May 01 pg 1436-45

    MeSH

    Adolescent
    Adult
    Carcinoma, Squamous Cell
    Female
    Head and Neck Neoplasms
    Hodgkin Disease
    Humans
    Kaplan-Meier Estimate
    Male
    Middle Aged
    Multivariate Analysis
    Neoplasms, Second Primary
    Proportional Hazards Models
    Risk Factors
    SEER Program
    Survivors
    Young Adult

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    25572913

    Citation

    Chowdhry, Amit K., et al. "Second Primary Head and Neck Cancer After Hodgkin Lymphoma: a Population-based Study of 44,879 Survivors of Hodgkin Lymphoma." Cancer, vol. 121, no. 9, 2015, pp. 1436-45.
    Chowdhry AK, McHugh C, Fung C, et al. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. Cancer. 2015;121(9):1436-45.
    Chowdhry, A. K., McHugh, C., Fung, C., Dhakal, S., Constine, L. S., & Milano, M. T. (2015). Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. Cancer, 121(9), pp. 1436-45. doi:10.1002/cncr.29231.
    Chowdhry AK, et al. Second Primary Head and Neck Cancer After Hodgkin Lymphoma: a Population-based Study of 44,879 Survivors of Hodgkin Lymphoma. Cancer. 2015 May 1;121(9):1436-45. PubMed PMID: 25572913.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. AU - Chowdhry,Amit K, AU - McHugh,Colin, AU - Fung,Chunkit, AU - Dhakal,Sughosh, AU - Constine,Louis S, AU - Milano,Michael T, Y1 - 2015/01/08/ PY - 2014/10/13/received PY - 2014/11/24/revised PY - 2014/11/25/accepted PY - 2015/1/10/entrez PY - 2015/1/13/pubmed PY - 2015/6/27/medline KW - Hodgkin lymphoma KW - head and neck cancer KW - salivary gland cancer KW - second malignancy KW - squamous cell carcinoma SP - 1436 EP - 45 JF - Cancer JO - Cancer VL - 121 IS - 9 N2 - BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at an increased risk of developing second malignancies. To the authors' knowledge, the risks of head and neck cancer (HNC) after HL and subsequent survival have not been thoroughly investigated. METHODS: From the US population-based Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2011, survivors of HL who developed HNC as a second cancer were analyzed. Patients with a first primary HNC were used as a comparison group. Observed-to-expected ratios and summary statistics were performed on patients with HL with squamous cell carcinoma (HL-SCC) and salivary gland cancer (HL-SGC). The impact of HL history on overall survival was assessed using a multivariate Cox proportional hazards model. RESULTS: The observed-to-expected ratio for SCC among patients with HL was 1.73 (95% confidence interval [95% CI], 1.36-2.16; P<.05), whereas it was 8.56 for SGC (95% CI, 5.82-12.15; P<.05). Using Cox proportional hazards modeling, a history of HL was found to be an adverse prognostic factor for overall survival for SCC (hazard ratio, 1.37; 95% CI, 1.08-1.73 [P = .009]) but not SGC (hazard ratio, 1.21; 95% CI, 0.82-1.79 [P = .34]). The inferior survival of the patients in the HL-SCC cohort appears to be attributable to more deaths from HL and other malignancies diagnosed after SCC. CONCLUSIONS: There is a significantly increased risk of salivary and nonsalivary HNC after HL, and worse survival for patients with HL-SCC versus those with a first primary SCC. Clinicians should be aware of the risks of HNC after HL. In the absence of evidence-based criteria, the authors recommend that survivors of HL undergo periodic head and neck examination. SN - 1097-0142 UR - https://www.unboundmedicine.com/medline/citation/25572913/Second_primary_head_and_neck_cancer_after_Hodgkin_lymphoma:_a_population_based_study_of_44879_survivors_of_Hodgkin_lymphoma_ L2 - https://doi.org/10.1002/cncr.29231 DB - PRIME DP - Unbound Medicine ER -